Come meet Dexcom at ISPAD 2026

Come get to know Dexcom on the show floor and explore what makes us the #1 CGM brand for pediatrics, as surveyed among European and North American HCPs1,†. See our portfolio in action, connect with our experts, and dive into our educational session focused on technology adoption in pediatric diabetes.

Dexcom Exclusive Symposium

Protecting the Next Generation: Early CGM, AID, and Practical Strategies for Pediatric Diabetes Care 

Friday, November 6, 2026 | 14:00-15:15
ExpoRio Cidade Nova, Session Room 3

Speakers:
Pablo Mora, MD, Anita Swamy, MD, Daniel DeSalvo, MD

Advances in continuous glucose monitoring (CGM) and automated insulin delivery (AID) have transformed the management of type 1 diabetes in children and adolescents. This session will review current evidence supporting early technology adoption, discuss evolving professional society recommendations, and explore practical strategies for integrating CGM and AID into pediatric diabetes care. Participants will examine considerations for technology implementation, patient and caregiver education, and maintaining technology use through key transitions in care. The program will also highlight how Dexcom CGM features such as remote monitoring and customizable alerts can support diabetes management. By the end of the session, attendees will be able to summarize current evidence for early CGM and AID use, discuss guideline-based approaches to technology adoption, and identify practical strategies to support successful implementation and ongoing engagement in pediatric populations.  
Learn More

Dexter the Dog's CGM Onboarding Guide 

A Dexcom onboarding guide designed for kids.

Select your language below to download Dexter the Dog’s CGM Onboarding Guide

Download English
Download Spanish
Side image

Discover the Dexcom Portfolio

Explore Dexcom

Questions?

If you have any questions, please contact Dexcom at events@dexcom.com
Dexcom is neither approved nor commercially available in Brazil. Please visit www.Dexcom.com/global for more information on international product availability.

*Results with Dexcom CGM have been proven in over 70 clinical studies, data available on clinicaltrials.gov.
† Findings based on NPS scores for HCPs

‡ Features include Urgent Low alert, Urgent Low Soon alert, Delay 1st High alert Rise/Fall Rate and Remote Monitoring
1. Dexcom Data on File, 2026
2. Dexcom Data on File, 2025
3. Norman GJ, et al. J Manag Care Spec Pharm. 2025;31(1):15-24.
4. Nemlekar PM, et al. Diabetes Technol Ther. 2026;28(Suppl 3):206S.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

MAT-17090